<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>医脉通血液科 | wechat-feeds</title><link>http://MjM5OTA3MzIwMA.favicon.privacyhide.com/favicon.ico</link><description>医脉通血液科主要提供国内外血液前沿资讯，热门血液指南，国内外血液会议报道，精彩血液病例！ “饕餮”血液，尽在医脉通血液科！</description><managingEditor> (hellodword)</managingEditor><pubDate>Fri, 05 Mar 2021 20:36:33 +0800</pubDate><image><url>http://MjM5OTA3MzIwMA.favicon.privacyhide.com/favicon.ico</url><title>医脉通血液科 | wechat-feeds</title><link>http://MjM5OTA3MzIwMA.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>大医精诚，无与“淋”比 | 淋巴瘤全程管理的探索者——中山大学肿瘤医院淋巴瘤亚专科团队</title><link>https://mp.weixin.qq.com/s/g6mBBGvOKtU0UM8naoYTjQ</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/oibBq71TGAe44FibkPVzR0FldcFjZR8sEric9uCnm78egzoVFhboONhXEe70cg06LeVm8lQiava8yPYk40KpkUAmsw/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>本期《大医精诚，无与“淋”比》带您走近中山大学肿瘤医院淋巴瘤亚专科！]]></content:encoded><pubDate>Fri, 05 Mar 2021 19:01:21 +0800</pubDate></item><item><title>伊沙妥昔单抗联合地塞米松显著改善复发难治多发性骨髓瘤患者疗效</title><link>https://mp.weixin.qq.com/s/KyIWxGqNPUv8VTUM16IGEw</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/oibBq71TGAe6dOCtBicz3mhSfJAbfxic5ibqUbJFGIS884CeHs9DKw9NGajRQLsKoiaGvHwekgt6WAgF6C7hS2nPgYA/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>一项II期研究对比了伊沙妥昔单抗单药方案和伊沙妥昔单抗联合地塞米松方案在RRMM患者中的疗效和安全性。现将该研究的主要结果整理如下，供广大读者参考。]]></content:encoded><pubDate>Fri, 05 Mar 2021 19:01:21 +0800</pubDate></item><item><title>急性GVHD的预防新方案 | PTCy、西罗莫司和MMF可显著降低急性GVHD的发生率</title><link>https://mp.weixin.qq.com/s/hmbhuLrtBTGHoi_OqFq1zw</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/oibBq71TGAe6dOCtBicz3mhSfJAbfxic5ibqk2pIuGuwh46nAUYOocTaFPEFhzpFeNmTbqia7hnW3CwP7cib0G9mafWw/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>一项2期研究评估了外周血haplo-HCT后PTCy+西罗莫司+MMF预防GVHD的效果。]]></content:encoded><pubDate>Fri, 05 Mar 2021 19:01:21 +0800</pubDate></item><item><title>【课程】《认识多发性骨髓瘤》，现在可看！</title><link>https://mp.weixin.qq.com/s/rmJZRNtLatJiXUMZEM_thQ</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/oibBq71TGAe6dOCtBicz3mhSfJAbfxic5ibqtiavedM8y0bmHedyzvbD4NibeJBmgiaA9fG14QAsEER3JrOicRE939Vbqg/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>本节课程您将了解到：骨髓瘤定义、血细胞发育过程、浆细胞发育过程及浆细胞异常相关问题。]]></content:encoded><pubDate>Fri, 05 Mar 2021 19:01:21 +0800</pubDate></item><item><title>穿越百年 | 带你走近慢粒的发展变革史</title><link>https://mp.weixin.qq.com/s/J2OTvb2-oSaYZTLy-t8zMA</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/oibBq71TGAe6rIn49bgIdPfbWkqbWgvTFVlIja8a5ztD25sdPibnJGasQs2qDdNo3KoNPEPEib7NjVhg1D51Wl7jA/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>本期《穿越百年》让我们一起走进慢粒的发展变革史。]]></content:encoded><pubDate>Thu, 04 Mar 2021 18:18:25 +0800</pubDate></item><item><title>CAR-T细胞疗法Idecabtagene Vicleucel治疗复发难治多发性骨髓瘤：II期KarMMa研究结果</title><link>https://mp.weixin.qq.com/s/iWCMHKLS-MmbCDcL9A9THg</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/oibBq71TGAe4IIUibWhKHGEzLlpSplchZ1JoMhr2fsJuibb8rs2zZu5QOFWyeQibtJ9zMP7icjcDyfGnAMtwkfUxr4w/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>一项关键性研究（KarMMa研究）探索了CAR-T细胞疗法Idecabtagene Vicleucel（ide-cel）在复发难治多发性骨髓瘤患者中的疗效和安全性。]]></content:encoded><pubDate>Thu, 04 Mar 2021 18:18:25 +0800</pubDate></item><item><title>CAR-T细胞毒副作用之感染 | CAR-T细胞治疗NHL毒副作用临床管理专家共识</title><link>https://mp.weixin.qq.com/s/KZihkIQHgyd1vu7b7wR6-w</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/oibBq71TGAe4IIUibWhKHGEzLlpSplchZ18iaBUrNzllVZJM0JvS7CSl4gFibibibqy8thHbK9z4xc6IkZwWl6h4y8Zg/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>一文读懂CAR-T细胞毒副作用之感染。]]></content:encoded><pubDate>Thu, 04 Mar 2021 18:18:25 +0800</pubDate></item><item><title>【限时活动】听说上传病例能兑换话费，还不快来？</title><link>https://mp.weixin.qq.com/s/-Kl8ihNm3bd3PjJ1paLXzw</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/oibBq71TGAe4IIUibWhKHGEzLlpSplchZ1lvldTibv0durciavJXIU94nPeQpdpaIsEib57uxOWxULZQlq7b1D3Au4g/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>医脉通病例交流版块诞生啦！]]></content:encoded><pubDate>Thu, 04 Mar 2021 18:18:25 +0800</pubDate></item><item><title>王建祥教授：多点开花，浅谈吉瑞替尼在FLT3突变阳性AML中应用</title><link>https://mp.weixin.qq.com/s/i4Plx452nUvGdfaHQGavRA</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/oibBq71TGAe7uw05ztdiaRJatYxKVfeAvsha9WicrXW23d9Ev852usft2qOGdGkWlXyiabuKOtYMk1NmFMib6squJLA/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>中国医学医学院血液病医院王建祥教授谈吉瑞替尼在FLT3突变阳性AML患者中的应用。]]></content:encoded><pubDate>Wed, 03 Mar 2021 17:11:17 +0800</pubDate></item><item><title>提高耐受性，改善疗效，RRMM患者的新选择：HDAC抑制剂+皮下注射硼替佐米+地塞米松</title><link>https://mp.weixin.qq.com/s/UIXrSDh6pbtpYlgcAufUqw</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/oibBq71TGAe6RNlozCVgcUsM6m6S98WEfhGiayQelmy96hJI4hWIC6zT6XjpkFkEGHNQd0OK3tXS7MgF9iaEhy1tw/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>口服panobinostat+皮下注射硼替佐米+口服地塞米松治疗RRMM疗效好，耐受佳。]]></content:encoded><pubDate>Wed, 03 Mar 2021 17:11:17 +0800</pubDate></item><item><title>CAR-T细胞毒副作用之HLH/MAS | CAR-T细胞治疗NHL毒副作用临床管理专家共识</title><link>https://mp.weixin.qq.com/s/5r-aNnqHecPtFubw8QTj_A</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/oibBq71TGAe6rIn49bgIdPfbWkqbWgvTFwaursRicibqLN7JXDGfwRQ2gsKyDALVmsUrsUStI298rcRMI4n888HkQ/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>一文读懂噬血细胞性淋巴组织细胞增生症/巨噬细胞活化综合征。]]></content:encoded><pubDate>Wed, 03 Mar 2021 17:11:17 +0800</pubDate></item><item><title>单倍型造血干细胞移植相较于同胞相合移植具有更强的移植物抗白血病作用</title><link>https://mp.weixin.qq.com/s/dasxjXT75X1k0CLBrM0XDw</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/oibBq71TGAe6RNlozCVgcUsM6m6S98WEfFofQwxmOsib7CibWN197XwEAwoAbOTAPNZuTm5f6xBNRCGYmd9KgeFtw/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>haplo-SCT中的免疫细胞相较于MSDT具有更强的抗白血病作用。]]></content:encoded><pubDate>Wed, 03 Mar 2021 17:11:17 +0800</pubDate></item><item><title>伊布替尼联合Ublituximab治疗复发难治高危慢性淋巴细胞白血病：III期GENUINE研究结果</title><link>https://mp.weixin.qq.com/s/BSZRgvF1rDFoTG0WFh7FNA</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/oibBq71TGAe6rIn49bgIdPfbWkqbWgvTFMzVgujNBBfcMv4KjESeNiciciaD59faecYupMIyChweLtSXL7mpkgnJjg/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>III期GENUINE研究对比了Ublituximab联合伊布替尼方案和伊布替尼单药方案治疗具有高危细胞遗传学因素的CLL患者的疗效，判断伊布替尼单药方案基础上联合Ublituximab能否改善这部分患者的预后。]]></content:encoded><pubDate>Tue, 02 Mar 2021 18:19:32 +0800</pubDate></item><item><title>新药时代CLL患者治疗前需要明确哪些事？</title><link>https://mp.weixin.qq.com/s/xPQSMqLqR-yGlb3nAh_Wnw</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/oibBq71TGAe6rIn49bgIdPfbWkqbWgvTFcV4Zo5AhYLwAksL97RlhUtCzVHGl4SdyOeV56A3oOYhNz6jAexfPPA/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>盘点在新药时代CLL患者治疗前到底需要明确哪些事。]]></content:encoded><pubDate>Tue, 02 Mar 2021 18:19:32 +0800</pubDate></item><item><title>FDA更新 | 加速批准Melphalan Flufenamide治疗复发难治性多发性骨髓瘤患者</title><link>https://mp.weixin.qq.com/s/BgWszt5d3bS4nDaQgQwkBg</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/oibBq71TGAe6rIn49bgIdPfbWkqbWgvTFNicEBwjUJGweibm1jWmWge9zkibo7EbVySTHTI2sQiblmibqMmEdB1J7TEg/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>FDA加速批准melphalan flufenamide联合地塞米松联治疗复发难治性多发性骨髓瘤成人患者。]]></content:encoded><pubDate>Tue, 02 Mar 2021 18:19:32 +0800</pubDate></item><item><title>CAR-T细胞毒副作用之CAR-T相关脑病综合征 | CAR-T细胞治疗NHL毒副作用临床管理专家共识</title><link>https://mp.weixin.qq.com/s/sRhjHjn7AAQYQSnzVFxYxg</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/oibBq71TGAe6rIn49bgIdPfbWkqbWgvTF6o8t9exlThuDBnlibzVTmdxNmShTDvIx3cq6XxXVH1VhdjM40UW7sqQ/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>一文读懂CAR-T相关脑病综合征。]]></content:encoded><pubDate>Tue, 02 Mar 2021 18:19:32 +0800</pubDate></item><item><title>维奈克拉联合伊布替尼治疗复发难治慢性淋巴细胞白血病：II期VISION研究结果</title><link>https://mp.weixin.qq.com/s/uPX_6KaJo3SaTZ9PyzBpIA</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/oibBq71TGAe6eicicUmwm6gtU8LewcTQukUjic0ibiapK200n9kxm7xXQn0Z2Knt9oGibJr9UAhUcdmAawIWlxqhUYmbQ/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>维奈克拉联合伊布替尼治疗复发难治慢性淋巴细胞白血病的II期VISION研究结果。]]></content:encoded><pubDate>Mon, 01 Mar 2021 18:17:44 +0800</pubDate></item><item><title>B细胞NHL治疗：NK细胞免疫疗法联合化疗和ASCT，能否实现“off-the-shelf”？</title><link>https://mp.weixin.qq.com/s/MRXBZEy9S4DKaXrst5z3sw</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/oibBq71TGAe6eicicUmwm6gtU8LewcTQukUH1tJicfS2bvpyjibQUwyQkHeeHVicA6eoOlriaInEaZlAKVPEoJ71mUZow/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>脐带血来源的自然杀伤细胞免疫疗法联合高剂量化疗和ASCT可诱导B细胞NHL的早期抗肿瘤反应。]]></content:encoded><pubDate>Mon, 01 Mar 2021 18:17:44 +0800</pubDate></item><item><title>CAR-T细胞毒副作用之CRS | CAR-T细胞治疗NHL毒副作用临床管理专家共识</title><link>https://mp.weixin.qq.com/s/2eGiyF-TXQOj5eG55QBQUA</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/oibBq71TGAe6eicicUmwm6gtU8LewcTQukUF8fvbs5tvcFWNia6O9cZ4ibRNV2icEvc6sVblKQnRQ3eFY9dHyoDyDjlA/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>一文读懂CAR-T细胞毒副作用之一CRS的分型与治疗。]]></content:encoded><pubDate>Mon, 01 Mar 2021 18:17:44 +0800</pubDate></item><item><title>3月1日起执行2020年医保药品目录，国产4款PD-1抑制剂全部进入医保行列</title><link>https://mp.weixin.qq.com/s/yOhzfzKL8bDziogchQpyIw</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/oibBq71TGAe6eicicUmwm6gtU8LewcTQukUtxYFKzOwJz3tr63plGBegYSPyCLSOdCaCVcYHjyibiccsLzKW5Qr17Ww/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>4种国产PD-1抑制剂——信迪利单抗、替雷利珠单抗、特瑞普利单抗、卡瑞利珠单抗全部进入医保行列。]]></content:encoded><pubDate>Mon, 01 Mar 2021 18:17:44 +0800</pubDate></item></channel></rss>